Skip to search boxSkip to navigationSkip to main content

Vaccination against myeloid leukaemias using newly defined antigens

  • Barbara Guinn
    ,
  • Susanne Hofmann
    ,
  • Ghazala Khan
    ,
  • Viktoriya Bogdanova Boncheva
    ,
  • Jochen Greiner
Research Output:
Chapter in Book/Report/Conference proceeding
Chapter
 Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

First complete remission rates are high in patients with acute myeloid leukaemia (AML), with some variation depending on the presence of specific cytogenetic and molecular aberrations. However, the remission is often not long lasting and relapse occurs after standard chemotherapy within two years. Besides chemotherapy, non-specific immunotherapy in the form of allogeneic haematopoietic stem cell transplantation (HSCT) is an integral part of consolidation and salvage therapy in the treatment of AML. A large number of leukaemia-associated antigens (LAAs) that can act as potential targets for specific immunotherapy have been identified, and the number is still increasing. To date, several of these antigens are being utilized in clinical vaccination trials, either as active specific immunotherapy in form of peptide vaccination or as passive specific immunotherapy as adoptive cell therapies. This chapter reviews the role of newly defined LAAs as well as the results of already performed clinical vaccination trials with known LAAs.

Publication Information

Output type

Research Output:
Chapter in Book/Report/Conference proceeding
Chapter
 Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 281-294

Publication milestones

  • Published - 01/01/2014

Publication status

Published - 01/01/2014

Publisher

Oxford University Press, India, United States, United Kingdom

ISBN (Print)

9780199676866

Publication IDs

  • handle.net: 10547/578856

Host publication title

Cancer Immunology Immunotherapy

Access to documents

Publication metrics